More about the Genmab Jan van de Winkel Scholarship Fund

Jan van de Winkel has been Professor of Immunotherapy at Utrecht University since 1996. He is widely recognized for his scientific achievements, including more than 180 patents and patent applications and more than 300 scientific articles. The scholarship fund honours his impactful career and is intended to support the next generation of scientific talent.

Genmab is a global player in the development of new cancer drugs and has been an important part of the very strong cluster of cancer research at Utrecht Science Park for 25 years. Genmab is working on the development of therapeutic antibodies, especially for the treatment of cancer. These antibodies are unique due to their special specificity for tumor cells and their great effectiveness in destroying them.

The excellent infrastructure at the Utrecht Science Park, the presence of a strong Faculty of Medicine and Veterinary Medicine, the Joint Animal Laboratory, and the large concentration of excellent researchers, students and PhD students within the Life Sciences site, were the deciding factors for us to permanently establish ourselves at the Utrecht Science Park.